Focused on ophthalmic therapeutics, the company develops and commercializes treatments for eye diseases using sustained-release drug delivery technology. Its portfolio includes FDA‑approved DEXTENZA for post-surgical ocular pain and inflammation and a pipeline of retinal disease candidates under cli...
2 members of Congress have disclosed 2 trades in Ocular Therapeutix, Inc. (OCUL), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2011-01-09 | Vern Buchanan | buy | $1K – $15K |
| 2010-08-11 | JAMES B. RENACCI | buy | $2,643.52 |